Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users - Services, U. S. Department of Health and
22,99 €
inkl. MwSt.

Versandfertig in über 4 Wochen
  • Broschiertes Buch

The treatment described in this manual was designed to address the problem of marijuana use by adolescents. Section I reviews the scope, effects, and patterns of the marijuana problem. Section II provides a brief overview of the Cannabis Youth Treatment project for which this manual was developed. Section III covers the scientific basis for this intervention. Section IV provides step-by-step procedures for actually implementing this treatment protocol.

Andere Kunden interessierten sich auch für
Produktbeschreibung
The treatment described in this manual was designed to address the problem of marijuana use by adolescents. Section I reviews the scope, effects, and patterns of the marijuana problem. Section II provides a brief overview of the Cannabis Youth Treatment project for which this manual was developed. Section III covers the scientific basis for this intervention. Section IV provides step-by-step procedures for actually implementing this treatment protocol.
Autorenporträt
TIP 63 Update--- To ensure that the content of this TIP is as up to date and as useful to readers as possible, SAMHSA, in January 2020, revised certain areas of all five parts. These changes will help provide readers with the latest information needed to understand medications for opioid use disorder. These changes included the following: . Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations. . Updating the expanded list of other qualifying practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives). . Clarifying that buprenorphine is available in an extended-release injection formulation. . Adding information about the use of subdermal formulations of buprenorphine (i.e., Probuphine and Sublocade). . Adding information about possible clinical interactions between formulations of buprenorphine and naltrexone with various other medications and products. . Improving the language to make clear the importance of testing for HIV and hepatitis C. . Updating recommendations from the U.S. Preventive Services Task Force on performing drug screening for adults in primary care settings. . Removing or replacing broken hyperlinks to online resources.